Short Interest in Interpace Biosciences, Inc. (OTCMKTS:IDXG) Decreases By 77.9%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 616 shares, a decline of 77.9% from the April 15th total of 2,793 shares. Based on an average daily volume of 10,517 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Interpace Biosciences Price Performance

IDXG traded down $0.10 on Thursday, reaching $1.80. 915 shares of the company traded hands, compared to its average volume of 8,356. The stock’s 50 day moving average price is $1.91 and its 200-day moving average price is $1.52. Interpace Biosciences has a 52-week low of $0.70 and a 52-week high of $2.40. The company has a market cap of $7.97 million, a price-to-earnings ratio of -90.00 and a beta of 0.65.

Interpace Biosciences (OTCMKTS:IDXG) last announced its quarterly earnings data on Tuesday, May 12th. The business services provider reported $0.03 EPS for the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 346.17%. The firm had revenue of $9.03 million for the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.